Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1888 1
1906 1
1956 2
1957 1
1962 2
1963 3
1964 12
1965 4
1966 1
1968 1
1969 3
1970 2
1971 3
1972 1
1973 4
1974 2
1975 7
1976 9
1977 7
1978 14
1979 2
1980 9
1981 12
1982 12
1983 18
1984 14
1985 15
1986 13
1987 16
1988 20
1989 12
1990 34
1991 22
1992 17
1993 23
1994 18
1995 31
1996 26
1997 24
1998 24
1999 20
2000 29
2001 37
2002 31
2003 40
2004 44
2005 50
2006 57
2007 71
2008 57
2009 53
2010 68
2011 75
2012 82
2013 103
2014 117
2015 163
2016 176
2017 187
2018 191
2019 181
2020 196
2021 223
2022 210
2023 182
2024 72

Text availability

Article attribute

Article type

Publication date

Search Results

2,872 results

Results by year

Filters applied: . Clear all
Page 1
m(6)A mRNA methylation controls T cell homeostasis by targeting the IL-7/STAT5/SOCS pathways.
Li HB, Tong J, Zhu S, Batista PJ, Duffy EE, Zhao J, Bailis W, Cao G, Kroehling L, Chen Y, Wang G, Broughton JP, Chen YG, Kluger Y, Simon MD, Chang HY, Yin Z, Flavell RA. Li HB, et al. Among authors: simon md. Nature. 2017 Aug 17;548(7667):338-342. doi: 10.1038/nature23450. Epub 2017 Aug 9. Nature. 2017. PMID: 28792938 Free PMC article.
N(6)-methyladenosine (m(6)A) is the most common and abundant messenger RNA modification, modulated by 'writers', 'erasers' and 'readers' of this mark. In vitro data have shown that m(6)A influences all fundamental aspects of mRNA metabolism, mainly mRNA stability, t …
N(6)-methyladenosine (m(6)A) is the most common and abundant messenger RNA modification, modulated by 'writers', 'erasers' and 'reade …
m(6)A-independent genome-wide METTL3 and METTL14 redistribution drives the senescence-associated secretory phenotype.
Liu P, Li F, Lin J, Fukumoto T, Nacarelli T, Hao X, Kossenkov AV, Simon MC, Zhang R. Liu P, et al. Among authors: simon mc. Nat Cell Biol. 2021 Apr;23(4):355-365. doi: 10.1038/s41556-021-00656-3. Epub 2021 Apr 1. Nat Cell Biol. 2021. PMID: 33795874 Free PMC article.
Methyltransferase-like 3 (METTL3) and 14 (METTL14) are core subunits of the methyltransferase complex that catalyses messenger RNA N(6)-methyladenosine (m(6)A) modification. Despite the expanding list of m(6)A-dependent functions of the methyltransferase complex, th …
Methyltransferase-like 3 (METTL3) and 14 (METTL14) are core subunits of the methyltransferase complex that catalyses messenger RNA N(6)-meth …
Bioaccumulation of therapeutic drugs by human gut bacteria.
Klünemann M, Andrejev S, Blasche S, Mateus A, Phapale P, Devendran S, Vappiani J, Simon B, Scott TA, Kafkia E, Konstantinidis D, Zirngibl K, Mastrorilli E, Banzhaf M, Mackmull MT, Hövelmann F, Nesme L, Brochado AR, Maier L, Bock T, Periwal V, Kumar M, Kim Y, Tramontano M, Schultz C, Beck M, Hennig J, Zimmermann M, Sévin DC, Cabreiro F, Savitski MM, Bork P, Typas A, Patil KR. Klünemann M, et al. Among authors: simon b. Nature. 2021 Sep;597(7877):533-538. doi: 10.1038/s41586-021-03891-8. Epub 2021 Sep 8. Nature. 2021. PMID: 34497420 Free PMC article.
CANOMAD: a neurological monoclonal gammopathy of clinical significance that benefits from B-cell-targeted therapies.
Le Cann M, Bouhour F, Viala K, Simon L, Tard C, Rossi C, Morel G, Lagrange E, Magy L, Créange A, Michaud M, Franques J, Echaniz-Laguna A, Antoine JC, Baron M, Arnulf B, Puma A, Delmont E, Maisonobe T, Leblond V, Roos-Weil D. Le Cann M, et al. Among authors: simon l. Blood. 2020 Nov 19;136(21):2428-2436. doi: 10.1182/blood.2020007092. Blood. 2020. PMID: 32959046 Free article.
CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) is a rare syndrome characterized by chronic neuropathy with sensory ataxia, ocular, and/or bulbar motor weakness in the presence of a monoc …
CANOMAD (chronic ataxic neuropathy, ophthalmoplegia, immunoglobulin M [IgM] paraprotein, cold agglutinins, and disialosyl antibodies) …
Signaling-specific inhibition of the CB1 receptor for cannabis use disorder: phase 1 and phase 2a randomized trials.
Haney M, Vallée M, Fabre S, Collins Reed S, Zanese M, Campistron G, Arout CA, Foltin RW, Cooper ZD, Kearney-Ramos T, Metna M, Justinova Z, Schindler C, Hebert-Chatelain E, Bellocchio L, Cathala A, Bari A, Serrat R, Finlay DB, Caraci F, Redon B, Martín-García E, Busquets-Garcia A, Matias I, Levin FR, Felpin FX, Simon N, Cota D, Spampinato U, Maldonado R, Shaham Y, Glass M, Thomsen LL, Mengel H, Marsicano G, Monlezun S, Revest JM, Piazza PV. Haney M, et al. Among authors: simon n. Nat Med. 2023 Jun;29(6):1487-1499. doi: 10.1038/s41591-023-02381-w. Epub 2023 Jun 8. Nat Med. 2023. PMID: 37291212 Free PMC article. Clinical Trial.
Non-M variants of human immunodeficiency virus type 1.
Mourez T, Simon F, Plantier JC. Mourez T, et al. Among authors: simon f. Clin Microbiol Rev. 2013 Jul;26(3):448-61. doi: 10.1128/CMR.00012-13. Clin Microbiol Rev. 2013. PMID: 23824367 Free PMC article. Review.
The AIDS pandemic that started in the early 1980s is due to human immunodeficiency virus type 1 (HIV-1) group M (HIV-M), but apart from this major group, many divergent variants have been described (HIV-1 groups N, O, and P and HIV-2). ...This, together with human a …
The AIDS pandemic that started in the early 1980s is due to human immunodeficiency virus type 1 (HIV-1) group M (HIV-M), but a …
Galunisertib plus neoadjuvant chemoradiotherapy in patients with locally advanced rectal cancer: a single-arm, phase 2 trial.
Yamazaki T, Gunderson AJ, Gilchrist M, Whiteford M, Kiely MX, Hayman A, O'Brien D, Ahmad R, Manchio JV, Fox N, McCarty K, Phillips M, Brosnan E, Vaccaro G, Li R, Simon M, Bernstein E, McCormick M, Yamasaki L, Wu Y, Drokin A, Carnahan T, To Y, Redmond WL, Lee B, Louie J, Hansen E, Solhjem MC, Cramer J, Urba WJ, Gough MJ, Crittenden MR, Young KH. Yamazaki T, et al. Among authors: simon m. Lancet Oncol. 2022 Sep;23(9):1189-1200. doi: 10.1016/S1470-2045(22)00446-6. Epub 2022 Aug 8. Lancet Oncol. 2022. PMID: 35952709 Clinical Trial.
Participants completed two 14-day courses of oral galunisertib 150 mg twice daily, before and during fluorouracil-based chemoradiotherapy (intravenous fluorouracil 225 mg/m(2) over 24 h daily 7 days per week during radiotherapy or oral capecitabine 825 mg/m(2) twice …
Participants completed two 14-day courses of oral galunisertib 150 mg twice daily, before and during fluorouracil-based chemoradiotherapy (i …
[Waldenström macroglobulinemia].
Telek B, Batár P, Váróczy L, Gergely L, Rejtő L, Szász R, Miltényi Z, Simon Z, Udvardy M, Illés A. Telek B, et al. Among authors: simon z. Orv Hetil. 2013 Dec 1;154(50):1970-4. doi: 10.1556/OH.2013.29776. Orv Hetil. 2013. PMID: 24317355 Hungarian.
2,872 results